Other3

Tonix Pharmaceuticals Holding Corp.

Total Value

$NaN

Filing Date

Sep 8, 2026

1 transactions

Trade Summary

On Sep 4, 2026, Englese Thomas, Chief Commercial Officer, reported $NaN of Tonix Pharmaceuticals Holding Corp. (TNXP) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Englese Thomas
Role: Chief Commercial Officer
Location: BERKELEY HEIGHTS, NJ

Filing Details

Filing Date: Sep 8, 2026
Transaction Date: Sep 4, 2026
Accession Number: 0001493152-26-041688
Form Type: 3

Want live alerts when Englese Thomas trades again?

Download Insider Trades to track TNXP, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The option was granted on September 9, 2024, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
(F2)The option was granted on February 25, 2025, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
(F3)The option was granted on May 13, 2025, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/4th on the first anniversary of issuance and 1/48th each month thereafter for 36 months.
(F4)The option was granted on February 24, 2026, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/4th on the first anniversary of issuance and 1/48th each month thereafter for 36 months.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Englese Thomas

(Last)

(First)

(Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP

200 CONNELL DRIVE, SUITE 3100

(Street)

BERKELEY HEIGHTS

07922

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/04/2026

3. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.001 par value per share	694	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option⁽¹⁾	09/09/2025	09/09/2034	Common Stock	500	$16.51	D
Stock Option⁽²⁾	02/25/2026	02/25/2035	Common Stock	6,500	$8.05	D
Stock Option⁽³⁾	05/13/2026	05/13/2035	Common Stock	12,480	$20.18	D
Stock Option⁽⁴⁾	02/24/2027	02/24/2036	Common Stock	40,000	$14.29	D

Explanation of Responses:

1. The option was granted on September 9, 2024, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.

2. The option was granted on February 25, 2025, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.

3. The option was granted on May 13, 2025, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/4th on the first anniversary of issuance and 1/48th each month thereafter for 36 months.

4. The option was granted on February 24, 2026, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/4th on the first anniversary of issuance and 1/48th each month thereafter for 36 months.

	/s/ Thomas Englese	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 as rendered by the SEC from accession 0001493152-26-041688.

Tonix Pharmaceuticals Holding Corp.

Trade Summary

Company Information

Insider Information

Filing Details

Want live alerts when Englese Thomas trades again?

Footnotes

SEC Form 3

SEC Filing

SEC Form 3